Swiss drugmaker Roche is advancing its experimental obesity drug CT-388 into a late-stage trial, aiming to compete with industry leaders Eli Lilly and Novo Nordisk. The company aims to capture ...

Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. The COVID-19 vaccine and ...